Diabetics with needle phobia and patients with severe problems in injection sites get benefited from Pfizer's Exubera, an inhaled insulin product (short-acting, powder form of insulin) - said The National Institute for Health and Clinical Excellence (NICE), Britain's watchdog.
A suggestion has already said by the National Institute for Health and Clinical Excellence (NICE) that inhaled insulin are not money worthy.
But now the revised report by the NICE says it can be used with flexibility - said Andrea Sutcliffe, deputy chief executive at NICE.
Both Type 1 and Type 2 diabetics can use Exubera, since it has got marketing licence in Europe and the United States.
A report from NICE (a center dealing with quality and its cost worth of treatments) say it costs more than its clinical use. So a single year per patient needs 1,102 pounds.
NICE have already been set reduced access to Alzheimer's drugs as pointing out on drugmakers and patient groups, now comes the Exubera proposal which has found to be the latest controversial ruling from NICE.
Since then 1920 Exubera only proved to benefit diabetic patients as well as clinicians by cutting on its treatment process and risks of complications - argued Pfizer.